Non-sleepy obstructive sleep apnoea: to treat or not to treat?

Nejat Altintas; Renata L Riha

doi:10.1183/16000617.0031-2019

Non-sleepy obstructive sleep apnoea: to treat or not to treat?

Eur Respir Rev. 2019 Dec 23;28(154):190031. doi: 10.1183/16000617.0031-2019. Print 2019 Dec 31.

Authors

Nejat Altintas¹, Renata L Riha^{2

3}

Affiliations

¹ Pulmonary and Sleep Medicine, Namik Kemal University, Tekirdag, Turkey.
² Dept of Sleep Medicine, Royal Infirmary of Edinburgh, Edinburgh, UK [email protected].
³ Centre for Clinical Brain Sciences, University of Edinburgh, Edinburgh, UK.

Abstract

Non-sleepy obstructive sleep apnoea (OSA) is thought to have a prevalence of around 20-25% in industrialised countries. However, the question of whether it should be routinely treated or not is controversial. This review collates the results from recent randomised controlled trials addressing OSA and examines whether treating the condition leads to improvements in quality of life and reduced cardiometabolic dysfunction, comorbidities generally attributed to untreated obstructive sleep apnoea/hypopnoea syndrome.

Publication types

Comparative Study
Review

MeSH terms

Aged
Clinical Decision-Making
Continuous Positive Airway Pressure / methods*
Female
Humans
Incidence
Male
Middle Aged
Polysomnography / methods
Prognosis
Quality of Life*
Randomized Controlled Trials as Topic
Risk Assessment
Severity of Illness Index
Sleep Apnea, Obstructive / diagnosis*
Sleep Apnea, Obstructive / epidemiology
Sleep Apnea, Obstructive / therapy*
Treatment Outcome
Watchful Waiting